140 studies whose primary subject is psychedelic-assisted therapy were published in 2023, up from 84 in 2022. Newest first. Back to the psychedelic-assisted therapy overview
Psychiatry, Depression & Anxiety December 30, 2023 Eyuel Terefe
we have combined the two (ketamine and CBT) in the form of ketamine-guided psychotherapy to successfully treat a patient with SCS in an acute suicidal state.
Psychiatria i Psychologia Kliniczna December 29, 2023 Paweł Holas
I address this letter to the Editorial Board of the “Journal of Psychiatry and Clinical Psychology” as an advocate of a critical yet hopeful approach to psychedelic-assisted therapy for the prevention and treatment of mental disorders. Global mental health is a key challenge of the 21st century. However, the available therapies are currently facing well-known limitations. The introduction of...
December 27, 2023 Owen S. Muir, Kenneth Shinozuka, Bryce D. Beutler et al. preprint
The reviews in this special edition have presented a primer on the state of the literature for six different psychedelic compounds and their plausible role in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader healthcare landscape for indicated conditions. Historically,...
December 26, 2023 Kirsten Cherian, Kenneth Shinozuka, Burton J. Tabaac et al. preprint
Background: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder (PTSD), depression, anxiety, and traumatic brain...
Clinical Psychology & Psychotherapy December 26, 2023 Sascha Thal, Paris Baker, Jonathon Marinis et al. 1 citation
Abstract Serotonergic psychedelics and related substances have been explored as potential adjuncts in substance‐assisted psychotherapy (SAPT) for treating various disorders. SAPT can be divided into three phases: preparation, administration and integration. Integration is commonly defined as the comprehension and effective application of insights from psychedelic experiences into everyday life....
December 26, 2023 Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. preprint
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause...
December 26, 2023 Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al. preprint
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psychosis, exemplified by the...
Revue Médicale Suisse December 20, 2023 Amandine Schaller, Géraldine Bourquin, Indira Amorim Araujo et al.
Depression, anxiety and existential distress associated with terminal illness have a major impact on quality of life among palliative care patients. Psychedelics are emerging as catalysts for reflective, introspective and sometimes spiritual exploration as part of psychotherapy, with potentially rapid and long-lasting multiple beneficial effects. Psychedelic-assisted psychotherapy (PAP)...
Journal of Psychedelic Studies December 14, 2023 Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower 1 citation
AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a...
Psychedelic Medicine December 13, 2023 Nicholas A. Carlisle, Haley Maria Dourron, Sarah Maccarthy et al. 12 citations
Recent trials of psychedelic-assisted therapy have suggested potential efficacy for the treatment of many health conditions that disproportionately impact sexual and gender minority (SGM) people, including major depressive disorder and alcohol and tobacco use disorders. Despite these promising findings, the potential benefits of psychedelics for SGM people have been largely ignored. First, we...
Psychedelic Medicine December 13, 2023 Andrew Penn, Rachel Yehuda 7 citations
The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT...
Canadian Journal of Bioethics December 7, 2023 Khaleel Rajwani 6 citations
In light of high-profile cases of sexual assault and other unethical conduct by therapists, recent clinical research involving psychedelic drugs has generally mandated the video recording of therapy sessions. In this paper, I address a gap in the literature by investigating ethical issues related to video recording in the unique context of psychedelic therapy sessions. I begin by summarizing...
Frontiers in Psychiatry December 6, 2023 Elliot Marseille, Manish Agrawal, Paul Thambi et al. 40 citations
Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician...
Journal of Military, Veteran and Family Health December 1, 2023 Zachary Skiles, James R Dixon, Dan Friedrich et al.
The field of psychedelic-assisted psychotherapy and state-run psychedelic services will need to adequately train and certify facilitators to meet the anticipated demand for access. This article explores the role of peer support in the setting of medical and non-medical supervised psychedelic administration. Existing peer-support frameworks from both the psychedelic and the Veteran communities...
Psychodynamic psychiatry December 1, 2023 John G Cottone
This case report details the treatment of a longtime psychodynamic psychotherapy patient, with a particular focus on a ketamine-assisted psychotherapy (KAP) session, and how the progress achieved during this session compares with the literature on KAP. The patient is a 54-year-old woman with a history of multiple traumas, including sexual assault and life-threatening physical injuries, as well...
Journal of Military, Veteran and Family Health December 1, 2023 Nicole S. Coverdale, Douglas J. Cook 3 citations
LAY SUMMARY Psychedelic pharmacotherapies combined with structured psychotherapy have shown promise in the treatment of several psychological conditions. This type of therapy is known as psychedelic-assisted psychotherapy (PAP) and includes three phases: preparation, in-session support, and integration. The purpose of this review was to identify randomized controlled trials (RCTs) that used...
Journal of Mood and Anxiety Disorders December 1, 2023 Sierra Carter, Grace Packard, Callan Coghlan et al. 18 citations
The present study investigated differences in perceptions of psychedelic-assisted therapy between Black and White Americans, as well as factors that may influence these perceptions. A final sample of 294 adults (42% female, 44% Black/African American or Mixed Race (of Black/African ancestry), 56% White American; Mage = 36.3 years) completed an online survey which assessed baseline knowledge and...
Palliative & Supportive Care December 1, 2023 Roxanne Sholevar, John R Peteet, Justin J. Sanders et al. 9 citations
Psychedelic-assisted therapies (PAT) are emerging as a promising treatment for psycho-existential distress in patients with serious illness. A recent qualitative analysis of perspectives of 17 experts in serious illness care and/or PAT research identified divergent views on the therapeutic potential and safety of PAT in patients with serious illness. This paper further analyzes the factors that...
Pharmacological Reports December 1, 2023 Justyna Holka-Pokorska 5 citations
In recent years, scientific research into the therapeutic potential of psychedelic compounds has experienced a resurgence of interest. New studies have shown promising results, supporting the use of psychedelic drugs in treating various psychiatric disorders, including treatment-resistant depression, post-traumatic stress disorder, and even alcohol addiction. The FDA has recognized...
Psychological Medicine December 1, 2023 Paul McCrone, Henry Fisher, Clare Knight et al. 34 citations
There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. A decision model simulated patient events (response, remission, and...